doi:10.1080/14737167.2021.1880324engTaxonera, Carlosde Andrés-Nogales, FernandoGarcía-López, SantiagoSánchez-Guerrero, AmeliaMenchén, BelénPeral, CarmenCábez, AnaGómez, SusanaLópez-Ibáñez de Aldecoa, AlejandraCasado, Miguel ÁngelMenchén, LuisCost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in SpainART-2022-122932Background: To evaluate the cost-effectiveness of tofacitinib in comparison to vedolizumab for the treatment of moderate-to-severe ulcerative colitis (UC) after failure or intolerance to conventional therapy (bio-naive) or first-line biologic treatment (bio-experienced), from the Spanish National Health System (NHS) perspective. Methods: A lifetime Markov model with eight-week cycles was developed including five health states: remission, response, active UC, remission after surgery, and death. Response and remission probabilities (for induction and maintenance periods) were obtained from a multinomial network meta-analysis. Drug acquisition – biosimilar prices included – (ex-factory price with mandatory deductions), adminis- tration, surgery, patient management, and adverse event management costs (€, year 2019) were considered. A 3% discount rate (cost/outcomes) was applied. Probabilistic and deterministic sensitivity analyses (PSA) were conducted. Results: Tofacitinib was dominant versus vedolizumab (both in bio-naive and bio-experienced patients) entailing total cost savings of €23,816 (bio-naïve) and €11,438 (bio-experienced). Differences in quality- adjusted life-year (QALY) were smaller than 0.1 for both populations. PSA results showed that tofacitinib has a high probability of being cost-effective (bio-naïve: 82.5%; bio-experienced: 90.6%) versus vedolizumab. Conclusions: From the Spanish NHS perspective, tofacitinib could be a dominant treatment (less costly and more effective) in comparison to vedolizumab, with relevant cost savings and similar QALY gains.2022http://zaguan.unizar.es/record/9976710.1080/14737167.2021.1880324http://zaguan.unizar.es/record/99767oai:zaguan.unizar.es:99767Expert Review of Pharmacoeconomics and Outcomes Research 22, 1 (2022), 73-83by-nc-ndhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/info:eu-repo/semantics/openAccess